Haemophilia A and B are rare congenital, recessive X-linked disorders caused by lack or
deficiency of clotting factor VIII (FVIII) or IX (FIX), respectively. The severity of the disease …

Haemophilia care has undergone substantial improvements during the past 40–50 years.
Early clotting factor concentrates were not sufficiently refined to enable self-administered …

Background: The large observed variability in hemophilia prevalence prevents robust
estimation of burden of disease. Objective: To estimate the prevalence and prevalence at …

Hemophilia is a rare disorder that is complex to diagnose and to manage. These evidence‐
based guidelines offer practical recommendations on the diagnosis and general …

Hemophilia A is a bleeding disorder resulting from coagulation factor VIII (FVIII) deficiency.
Exogenously provided FVIII effectively reduces bleeding complications in patients with …

Abstract Introduction The World Federation of Hemophilia (WFH) strives to achieve care for
all patients with inherited bleeding disorders through research, advocacy, capacity building …

Hemophilia is a congenital clotting factor deficiency characterized by spontaneous and
trauma-related bleeding. Spontaneous bleeding shows a predilection for joints, and …

Six recombinant factor VIII (rFVIII) products have been marketed worldwide. In 2013, the
Research of Determinants of Inhibitor Development (RODIN) study group reported an …

For decades, the monogenetic bleeding disorders hemophilia A and B (coagulation factor
VIII and IX deficiency) have been treated with systemic protein replacement therapy. Now …

Hemophilia A is a monogenic disease with a blood clotting factor VIII (FVIII) deficiency
caused by mutation in the factor VIII (F8) gene. Current and emerging treatments such as …